# OnCo record psma-pet-expression (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/psma-pet-expression/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "psma-pet-expression" ;
  schema:name "PSMA expression by PET (PSMA-positive)"@en ;
  schema:alternateName "PSMA PET positive"@en, "PSMA-positive"@en, "PSMA expression"@en, "PSMA PET"@en, "Ga-68 PSMA-11 uptake"@en, "piflufolastat PET"@en, "PSMA-avid"@en, "PSMA uptake greater than liver"@en ;
  schema:description "PSMA-positive means prostate cancer deposits light up on a PSMA PET scan more than the liver does. It is the entry ticket for lutetium-177 PSMA therapy and the basis of the imaging that now stages most advanced prostate cancer."@en ;
  schema:url <https://onco.cc/biomarkers/psma-pet-expression/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a> ;
  onco:tag "biomarker", "pet" ;
  onco:related <https://onco.cc/biomarkers/sstr-pet-expression/>, <https://onco.cc/biomarkers/ar-v7-splice-variant/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/prostate-mhspc/>, <https://onco.cc/cancers/prostate-bcr/> ;
  onco:drugs <https://onco.cc/drugs/pluvicto/>, <https://onco.cc/drugs/ga68-psma-11/>, <https://onco.cc/drugs/locametz/>, <https://onco.cc/drugs/illuccix/>, <https://onco.cc/drugs/pylarify/>, <https://onco.cc/drugs/flotufolastat/>, <https://onco.cc/drugs/lu177-psma-it/>, <https://onco.cc/drugs/ac225-psma/> ;
  onco:terms <https://onco.cc/terms/theranostics/>, <https://onco.cc/terms/prrt-term/> .